ARS Pharms Stock Price, News & Analysis

ARS Pharmaceuticals (NASDAQ:SPRY) has reported compelling real-world evidence for its neffy® (epinephrine nasal spray) in treating anaphylaxis. The study, accepted for publication in the Annals of Allergy, Asthma and Immunology, demonstrated that 89.2% of 545 patients experiencing anaphylaxis during oral food challenges and allergen immunotherapy were successfully treated with a single dose of neffy.

This success rate closely mirrors the 88.9% efficacy rate historically reported for traditional epinephrine injections, suggesting clinical interchangeability between the two delivery methods. The findings build upon previous clinical evidence, including a Phase 3 study, and represent the first large-scale analysis of neffy's treatment outcomes in routine clinical practice.

ARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company focused on anaphylaxis prevention, announced its participation in two upcoming investor conferences. The company's leadership will present at the Cantor Global Healthcare Conference on September 3, 2025, at 3:55 p.m. ET in New York, and the Stifel Immunology and Inflammation Summit on September 15, 2025, at 12:00 p.m. ET virtually.

Co-Founder, President and CEO Richard Lowenthal and Chief Commercial Officer Eric Karas will represent the company. Live webcasts will be available on the company's website, with replays accessible for 30 days after each event.

ARS Pharmaceuticals (NASDAQ: SPRY) reported strong Q2 2025 financial results, highlighting significant growth for neffy®, their needle-free epinephrine nasal spray. The company achieved $15.7 million in total revenue, including $12.8 million from U.S. neffy sales. Key commercial milestones include 93% commercial coverage and a 180% increase in prescription volumes from Q1 to Q2 2025.

The company has expanded globally with EURneffy® approval in the UK and launch in Germany. Financial position remains strong with $240.1 million in cash and investments, supporting operations for at least three years despite a net loss of $44.9 million for the quarter. The company has initiated a Phase 2b trial for urticaria and expects additional regulatory approvals in Canada, Japan, Australia, and China by 2026.

ARS Pharmaceuticals (Nasdaq: SPRY), a biopharmaceutical company focused on anaphylaxis prevention, will host a conference call and webcast to discuss its Q2 2025 financial results on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET.

Participants can register for the event to receive dial-in information. The webcast and presentation slides will be accessible through the Events & Presentations page on the company's website, with a replay available for 30 days after the event.

ARS Pharmaceuticals (NASDAQ:SPRY) has achieved a significant milestone as the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved EURneffy, the first needle-free adrenaline nasal spray for emergency treatment of allergic reactions. The approval covers adults and children weighing over 30 kg.

The company's partnership with ALK-Abelló A/S includes a $145 million upfront payment and potential additional payments of up to $320 million in milestones, plus tiered double-digit royalties. The UK represents the largest market outside the US for adrenaline auto-injector sales. EURneffy's launch is expected in late Q3 2025.

The product offers advantages including temperature stability up to 50°C and longer shelf life compared to auto-injectors. Additional regulatory approvals are anticipated in Canada, Japan, and Australia by end of 2025, with China following in 2026.

ARS Pharmaceuticals (NASDAQ: SPRY), a biopharmaceutical company focused on developing solutions for anaphylaxis prevention, has announced its participation in three upcoming investor conferences in June 2025:

• William Blair 45th Annual Growth Stock Conference in Chicago on June 3, 2025 at 11:20 a.m. CT
• 2025 Jefferies Global Healthcare Conference in New York City on June 4, 2025 at 5:30 p.m. ET
• Scotiabank Third Annual Healthcare Canadian Investor Day in Toronto on June 17, 2025

Company executives Richard Lowenthal (Co-Founder, President and CEO) and Eric Karas (Chief Commercial Officer) will lead presentations at the William Blair and Jefferies conferences. Live and archived webcasts will be available on the company's website for 30 days following each event.

ARS Pharmaceuticals (NASDAQ: SPRY) reported Q1 2025 financial results and progress in the U.S. launch of neffy®, their FDA-approved needle-free epinephrine nasal spray. The company achieved $7.8 million in neffy U.S. net product revenue. Key highlights include: nationwide availability of neffy 1mg for children aged 4+ and 2mg for adults, co-promotion agreement with ALK-Abelló reaching nearly 20,000 healthcare providers, and over 5,000 prescribing physicians to date. Financial results show $275.7 million in cash reserves with runway for 3+ years, though the company reported a net loss of $33.9 million. Commercial progress includes 57% commercial coverage, with United Healthcare added April 1st, and over 1,000 schools enrolled in the neffyinSchools program. The company plans to launch a comprehensive DTC marketing campaign and expects regulatory decisions in multiple international markets throughout 2025-2026.

ARS Pharmaceuticals (NASDAQ: SPRY) has announced the U.S. availability of neffy® 1 mg, their FDA-approved nasal spray epinephrine for Type I allergic reactions and anaphylaxis in children aged 4+ years weighing 15-30 kg. The needle-free design eliminates the risk of accidental injections, which affects ~3,500 cases annually. Key features include:

- 100% successful dosing rate in human factor studies - 24-month shelf life with temperature tolerance up to 122°F - Available at $199 for two doses (GoodRx price) - Eligible commercially insured patients pay as little as $25 - Partnership progress with major insurers including United Healthcare and Express Scripts

The company is implementing comprehensive support programs, including financial assistance and a Patient Assistance Program for eligible uninsured patients. The neffyinSchools program will provide the medication to participating eligible schools.

ARS Pharmaceuticals (NASDAQ: SPRY), a biopharmaceutical company focused on developing solutions for anaphylaxis protection, has scheduled a conference call and webcast for Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET. The event will cover the company's first quarter 2025 financial results and business highlights.

Participants can obtain dial-in information by registering for the event. The webcast and presentation slides will be accessible through the Events & Presentations page in the Investors & Media section of the company's website. A replay will remain available for 30 days after the event.